文献速递淋巴瘤

非霍奇金淋巴瘤患者的疫苗接种管理

Management of vaccinations in patients with non-Hodgkin lymphoma.
PubMed 文献 · Br J Haematol · 2024-03-26

本文综述了非霍奇金淋巴瘤(NHL)患者接种COVID-19及其他疫苗的有效性数据,指出抗CD20单克隆抗体治疗后疫苗诱导的免疫应答显著降低,并提出了多学科团队-based的疫苗接种管理建议。

要点

  • NHL患者接种疫苗是预防感染的重要手段,COVID-19大流行提高了对疫苗接种的认识。
  • 抗CD20单克隆抗体治疗后疫苗诱导的免疫应答显著降低。
  • 本文提出多学科团队-based的NHL患者疫苗接种管理建议。

核心结论

  • 抗CD20单克隆抗体治疗后疫苗诱导的免疫应答显著降低,需 refined 免疫策略。

研究设计与样本

  • 综述,总结NHL患者中COVID-19及其他疫苗有效性的现有数据。

主要发现

  • 多项研究证实抗CD20单克隆抗体治疗后疫苗诱导的免疫应答显著降低。

临床怎么用

  • 提出多学科团队-based的NHL患者疫苗接种管理建议。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Vaccinations are fundamental tools in preventing infectious diseases, especially in immunocompromised patients like those affected by non-Hodgkin lymphomas (NHLs). The COVID-19 pandemic made clinicians increasingly aware of the importance of vaccinations in preventing potential life-threatening SARS-CoV-2-related complications in NHL patients. However, several studies have confirmed a significant reduction in vaccine-induced immune responses after anti-CD20 monoclonal antibody treatment, thus underscoring the need for refined immunization strategies in NHL patients. In this review, we summarize the existing data about COVID-19 and other vaccine's efficacy in patients with NHL and propose multidisciplinary team-based recommendations for the management of vaccines in this specific group of patients.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Merli M, Costantini A, Tafuri S, et al. Management of vaccinations in patients with non-Hodgkin lymphoma. Br J Haematol. 2024. PMID: 38532527. doi:10.1111/bjh.19422

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。